semaglutide for heart failure Weight loss drug Wegovy helps people with common type of failure, trial finds New Science Suggests Semaglutide Improves

A dual ANCC board-certified NP walks through what to do when insurance denies a GLP-1 medication: how to read the denial, what documentation helps, and when to appeal.

The seller provides no medical advice, dosing guidance, or therapeutic claims

and Canada say theyve seen growing numbers of patients on the weight-loss drugs who inhaled food and liquid into their lungs while sedated because their stomachs were still full

This fact paved the way for the development of a GIP receptor agonist-based therapy for T2DM, looking also for the possibility of finding a combined GLP-1/GIP receptor agonist

Last week, Eli Lillys orforglipron has become the first oral, non-peptide GLP-1 receptor agonist to clear a Phase 3 trial, showing strong efficacy in reducing A1C (up to 1.6%) and body weight (up to 7.9%) in people with type 2 diabetes

Retatrutide has cleared a large hurdle in TRANSCEND-T2D-1, the first phase III trial testing the triple hormone receptor agonist in patients with type 2 diabetes, according to new top-line results released today by Lilly